ATG2B

Across TCGA pan-cancer cohorts, ATG2B Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated ATG2B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ATG2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATG2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SARC, UCEC, and KICH are the cancer types where ATG2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.153	0.747	<.001	15	view →
UCEC	DFS	Median	All	0.776	0.630	.010	14	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BRCA	OS	Median	III,IV	0.156	0.554	.006	12	view →
LIHC	OS	Median	II,III,IV	0.178	0.695	.019	9	view →
THCA	OS	Median	All	0.593	0.952	<.001	6	view →
ESCA	DFS	Median	III,IV	0.023	0.443	<.001	6	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →
COAD	OS	Median	III,IV	0.527	0.792	.007	5	view →
SKCM	DFS	Median	III,IV	0.054	0.656	<.001	5	view →
SCLC	OS	Median	All	0.315	0.655	.041	3	view →
LUSC	OS	Median	II,III,IV	0.500	0.748	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

ATG2B–SARC (OS)

Open the SARC breakdown →